From Medscape General Medicine

eJIAS: eJournal of the International AIDS Society

Brief Communication: Economic Comparison of Opportunistic Infection Management With Antiretroviral Treatment in People Living With HIV/AIDS Presenting at an NGO Clinic in Bangalore, India

Posted 11/01/2006

K.R. John, MD; Nirmala Rajagopalan, FHM, MBBS; Madhuri K.V., BSc
Author Information

Abstract

Context: Highly active antiretroviral treatment (HAART) usage in India is escalating. With the government of India launching the free HAART rollout as part of the "3 by 5" initiative, many people living with HIV/AIDS (PLHA) have been able to gain access to HAART medications. Currently, the national HAART centers are located in a few district hospitals (in the high- and medium-prevalence states) and have very stringent criteria for enrolling PLHA. Patients who do not fit these criteria or patients who are too ill to undergo the prolonged wait at the government hospitals avail themselves of nongovernment organization (NGO) services in order to take HAART medications. In addition, the government program has not yet started providing second-line HAART (protease inhibitors). Hence, even with the free HAART rollout, NGOs with the expertise to provide HAART continue to look for funding opportunities and other innovative ways of making HAART available to PLHA. Currently, no study from Indian NGOs has compared the direct and indirect costs of solely managing opportunistic infections (OIs) vs HAART.
Objective: Compare direct medical costs (DMC) and nonmedical costs (NMC) with 2005 values accrued by the NGO and PLHA, respectively, for either HAART or exclusive OI management.
Study design: Retrospective case study comparison.
Setting: Low-cost community care and support center -- Freedom Foundation (NGO, Bangalore, south India).
Patients: Retrospective analysis data on PLHA accessing treatment at Freedom Foundation between January 1, 2003 and January 1, 2005. The HAART arm included case records of PLHA who initiated HAART at the center, had frequent follow-up, and were between 18 and 55 years of age. The OI arm included records of PLHA who were also frequently followed up, who were in the same age range, who had CD4+ cell counts < 200/microliter (mcL) or an AIDS-defining illness, and who were not on HAART (solely for socioeconomic reasons). A total of 50 records were analyzed. Expenditures on medication, hospitalization, diagnostics, and NMC (such as food and travel for a caregiver) were calculated for each group.
Results: At 2005 costs, the median DMC plus NMC in the OI group was 21,335 Indian rupees (Rs) (mean Rs 24,277/-) per patient per year (pppy) (US $474). In the HAART group, the median DMC plus NMC was Rs 18,976/- (mean Rs 21,416/-) pppy (US $421). Median DMC plus NMC pppy in the OI arm was Rs 13623.7/- paid by NGO and Rs 1155/- paid by PLHA. Median DMC and NMC pppy in the HAART arm were Rs 1425/- paid by NGO and Rs 17,606/- paid by PLHA.
Conclusions: Good health at no increased expenditure justifies providing PLHA with HAART even in NGO settings.

Readers are encouraged to respond to George Lundberg, MD, Editor of MedGenMed, for the editor's eye only or for possible publication via email: glundberg@medscape.net

 
[ CLOSE WINDOW ]

References

  1. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. HIV estimates in India for year 2004 is 5.134 million infections. Available at: http://www.nacoonline.org/facts_hivestimates04.htm Accessed October 19, 2006.
  2. Kumarasamy N, Vallabhaneni S, Flanigan TP, Mayer KH, Solomon S. Clinical profile of HIV in India. Indian J Med Res. 2005;121:377-394. Available at: http://icmr.nic.in/ijmr/2005/April/0414.pdf Accessed October 19, 2006.
  3. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. Available at: http://www.nacoonline.org/index.htm Accessed October 19, 2006.
  4. Bhuyan A. Policy Project: Commitment for Action: Assessing Leadership for Confronting the HIV/AIDS Epidemic -- Lessons Learned From Pilot Studies in Bangladesh, India, Nepal, and Viet Nam. June 2005. Available at: http://www.policyproject.com/pubs/PoliticalCommitment/PC_Synthesis.pdf Accessed October 19, 2006.
  5. U.S. Department of Health and Human Services. Guidelines for initiating HAART. Available at: http://hab.hrsa.gov/publications/womencare05/WG05chap4.htm#WG05chap4e Accessed October 19, 2006.
  6. JournAIDS. Recommendations for initiating HAART and opportunistic infections seen. US Agency for International Development (USAID). Available at: http://www.journaids.org/treatment.php Accessed October 19, 2006.
  7. Attawell K, Mundy J. WHO and the UK's Department for International Development. Provision of antiretroviral therapy in resource-limited settings: a review of experience up to August 2003. Available at: http://www.who.int/3by5/publications/documents/en/ARTpaper_DFID_WHO.pdf Accessed October 19, 2006.
  8. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. The national free HAART program aims at reaching 100,000 eligible PLHA over 5 years. Available at: http://www.nacoonline.org/directory_arv.htm Accessed September 2005.
  9. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. ART centers in India. Available at: http://www.nacoonline.org/directory_arv.htm Accessed October 19, 2006.
  10. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. Number of AIDS cases in India in December 2004. Available at: http://www.nacoonline.org/facts_reportdec.htm Accessed October 19, 2006.
  11. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. National guidelines for anti-retro-viral treatment. Available at: http://www.nacoonline.org/guidelines/guideline_1.pdf Accessed October 19, 2006.
  12. Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS. 1999;13:1115-1122. Abstract
  13. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 1999;13:963-969. Abstract
  14. Merito M, Bonaccorsi A, Pammolli F, et al. Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. Health Policy. 2005;74:304-313. Abstract
  15. Kombe G, Galaty D, Nwagbara C. Scaling up Antiretroviral Treatment in the Public Sector in Nigeria: A Comprehensive Analysis of Resource Requirements. Partners for Health Reformplus, Federal Ministry of Health Nigeria. February 2004. Available at: http://www.phrplus.org/Pubs/Tech037_fin.pdf Accessed October 19, 2006.
  16. Freedom Foundation Annual Report. April 2003-April 2004. Published by the Freedom Foundation. A copy can be provided on request.
  17. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. Guidelines for community care centers. Available at: http://www.nacoonline.org/guidelines/guideline_6.pdf Accessed June 21, 2006.
  18. Patton MQ. Qualitative Evaluation and Research Methods. 2nd ed. Newbury Park, Calif: Sage Publications; 1990.
  19. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. New York: Oxford Medical Publications; 1990.
  20. Cheek RB. Playing God with HIV rationing HIV treatment in Southern Africa. Security Rev. 2001;10(4).
  21. Ramadhani HO, Thielman NM, Gao F, et al. Predictors of virologic failure and HIV drug resistance among patients receiving fixed dose combination stavudine/lamivudine/nevirapine in northern Tanzania. Available at: http://www.aids2006.org/PAG/PSession.aspx?s=263 Accessed October 19, 2006.
  22. Levi GC, Vitoria MAA. Fighting against AIDS: the Brazilian experience. AIDS. 2002;16:2373-2383. Abstract
  23. HAART: a cost-effective option for South Africa. PLoS Med. 2006;3(1). Available at: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030037 Accessed September 14, 2006.
  24. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for care of HIV-seropositive patients. the impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Pharmacoeconomics. 1999;16:307-315. Abstract
  25. Krentz HB, Auld MC, Gill MJ; HIV Economic Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ. 2003;169:106-110. Abstract
  26. Hansen K, Chapman G, Chitsike I, Kasilo O, Mwaluko G. The costs of HIV/AIDS care at government hospitals in Zimbabwe. Health Policy Plan. 2000;15:432-440. Abstract
  27. Youle M. Health economics and resource allocation. Medscape Conference Coverage, based on selected sessions at the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa. Available at: http://www.medscape.com/viewarticle/418966 Accessed September 14, 2006.
  28. Morris CN, Cheevers EJ. The direct costs of HIV/AIDS in a South African sugar mill. AIDS Anal Afr. 2000;10:7-8. Abstract
  29. Wikipedia. Economic impact of HIV. Available at: http://en.wikipedia.org/wiki/AIDS Accessed April 2006.
  30. Over M, Marseille E, Gold J, et al. HIV/AIDS Treatment and Prevention in India: Modeling the Costs and Consequences. Washington, DC: World Bank Publication; 2004.
  31. Ekong E, Idemyor V, Akinlade O, Uwah A. Challenges to antiretroviral drug therapy in resource-limited settings: the Nigerian experience. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 596.
  32. Durgavich J, O'Hearn T, Nigeria: Rapid Assessment of HIV/AIDS Care in the Public and Private Sectors. Washington, DC: US Agency for International Development (USAID)/Nigeria; August 2004. Available at: http://pdf.dec.org/pdf_docs/PNADA590.pdf Accessed June 23, 2006.
[ CLOSE WINDOW ]

Related Links

[ CLOSE WINDOW ]

Author Information

K.R. John, MD, Professor and Health Economist, Community Medicine, Christian Medical College, Vellore, India

Nirmala Rajagopalan, FHM, MBBS, Fellowship in HIV Medicine, HIV/AIDS Programme Manager, Freedom Foundation, Hennur Cross, Bangalore, India

Madhuri K.V., BSc, Project Coordinator, Freedom Foundation, Hennur Cross, Bangalore, India

Disclosure: K.R. John, MD, has disclosed no relevant financial relationships.

Disclosure: Nirmala Rajagopalan, FHM, MBBS, has disclosed no relevant financial relationships.

Disclosure: Madhuri K.V., BSc, has disclosed no relevant financial relationships.

Medscape General Medicine.  2006;8(4):24.  ©2006 Medscape

 
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.
No Java Scripts variables been set